Effect of rivaroxaban and warfarin on NT-proBNP,D-D and Fg levels after intervention in ACS patients
Objective To analyze the effects of rivaroxaban and warfarin on the levels of N-termi-nal pro-B-type natriuretic peptide(NT-proBNP),D-dimer(D-D)and fibrinogen(Fg)in patients with acute coronary syndromes(ACS)after intervention.Methods A total of 142 patients with ACS who underwent per-cutaneous coronary intervention were selected from Wusheng County People's Hospital from July 2020 to Febru-ary 2023.Following the principle of the single-blind method,they were divided into a control group of 70(treated with warfarin)and an observation group of 72(treated with rivaroxaban),based on different treatment regimens.Clinical efficacy,lipid levels[triglyceride(TG),total cholesterol(TC),low density lipoproteins cholesterol(LDL-C),high density lipoproteins cholesterol(HDL-C)],NT-proBNP,D-D,Fg levels,adverse cardiovascular events during the follow-up period and adverse events during the administration of the drug were compared between the two groups.The study also evaluated density lipoproteins cholesterol(HDL-C)],NT-proBNP,D-D,and Fg levels,adverse cardiovascular events during follow-up,and the occurrence of adverse re-actions during drug administration.Results The clinical effective rate of the observation group after treatment was higher than that of the control group(P<0.05).After 3 months of treatment,the levels of TG,TC,LDL-C,and HDL-C of the two groups decreased,and the observation group was lower than the control group(P<0.05).After 3 months of treatment,the levels of NT-proBNP,D-D,and Fg decreased in both groups,with the onser-vation group showing lower levels than in the control group,a statistically significant difference(P<0.05).The total incidence of cardiovascular adverse events during treatment was lower in the observation group than in the control group(14.28%),with a statistically significant difference(P<0.05).The overall incidence of adverse reactions during drug administration was lower in the observation group than in the control group(P<0.05).Conclusion The therapeutic effect of applying rivaroxaban after interventional therapy in ACS patients is more significant.It can effectively improve the blood lipid level and coagulation function of patients,as well as re-duce the risk of cardiovascular adverse events.
NETL
NSTL
万方数据
